ClinicalTrials.gg
CompletedNCT06568731Updated Jan 20, 2025

A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity

A Phase 1 interventional study of Danuglipron in Obesity, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Obesity by Pfizer — 13 open to participants now, 19 under way, 12 of them phase 3. Obesity · Pfizer.

Enrollment
53rd of 62
23 · median 127
Started
2024
with 6 others
Phase 1
30 of 64
3 open now
Registered
36th of 64
by date

Among the 64 studies in Obesity by Pfizer, this one is the 53rd largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2024, is one of 30 in phase 1, and was the 36th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

13 of the 64 studies in Obesity by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Obesity by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese:

  • how the study medicine, danuglipron, is taken up into the blood
  • about the safety and tolerability of danuglipron

The total number of weeks of the study is about 15 (about 4 months).

03

Conditions studied

  • Obesity

Keywords

  • Overweight
  • Obesity
  • Danuglipron
  • GLP-1
  • Overtly healthy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • 18 years of age or older
  • (BMI) of ≥25.0-45.4 kg/m2; and a total body weight >50 kg (110 lb)

Key Exclusion Criteria:

  • Evidence or history of any medical conditions or laboratory abnormality
  • Any condition possibly affecting drug absorption
  • Known intolerance/ to a GLP-1R agonist
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Single Arm

    Participants will receive multiple doses of danuglipron

    Drug: Danuglipron

Interventions

  • Danuglipron oral tablets

    Also known as: PF-06882961

06

What researchers measure

Primary outcomes

  1. Steady-state area under the concentration-time profile from time zero to 24 hours (AUC24) for danuglipron

    Time frame: Predose to 24 hours post danuglipron administration

  2. Steady-state maximum observed concentration (Cmax) for danuglipron

    Time frame: Predose to 24 hours post danuglipron administration

  3. Steady-state time to reach maximum observed concentration (Tmax) for danuglipron

    Time frame: Predose to 24 hours post danuglipron administration

Secondary outcomes

  1. Number of participants reporting Treatment Emergent Adverse Events (TEAEs)

    Time frame: From baseline up to 28-35 days post last dose taken

  2. Number of participants reporting clinically significant clinical laboratory abnormalities

    Time frame: From baseline up to 28-35 days post last dose taken

  3. Number of participants reporting clinically significant vital sign abnormalities

    Time frame: From baseline up to 28-35 days post last dose taken

  4. Change from baseline in body weight

    Time frame: From baseline up to 28-35 days post last dose taken

  5. Number of participants reporting clinically significant changes ECG abnormalities

    Time frame: From baseline up to 28-35 days post last dose taken

07

Study locations

1 site
  • Pfizer Clinical Research Unit - New Haven
    New Haven, Connecticut 06511, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Dec 2024, 3 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 23, 2024
StartActual
Aug 23, 2024
Primary completionActual
Dec 18, 2024
CompletionActual
Dec 18, 2024
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06568731
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Aug 23, 2024
Primary completion
Dec 18, 2024
Completion
Dec 18, 2024
Last update
Jan 20, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danuglipron

Start the discussion